Optimizing Detection and Prediction of Changes in Cognitive Function in Multiple Sclerosis (MS)

Sponsor
University of Michigan (Other)
Overall Status
Recruiting
CT.gov ID
NCT05252195
Collaborator
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (NIH), Wayne State University (Other), University of Washington (Other)
250
3
57.2
83.3
1.5

Study Details

Study Description

Brief Summary

The researchers will use technology-assisted ambulatory assessment techniques to examine cognitive dysfunction in people with Multiple Sclerosis (MS).

The researchers will determine if ambulatory assessments are sensitive to subtle declines in cognitive functioning. They will also explore the impact of modifiable factors, such as sleep, physical activity, mood, and somatic symptoms on cognitive function. These efforts will uncover behavioral and medical intervention methods. Finally, they will explore whether variability in cognitive functioning predicts short- and long-term changes in other patient-centered functional domains, social participation and physical functioning.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    250 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Optimizing Detection and Prediction of Changes in Cognitive Function in Multiple Sclerosis
    Actual Study Start Date :
    May 24, 2022
    Anticipated Primary Completion Date :
    Mar 1, 2027
    Anticipated Study Completion Date :
    Mar 1, 2027

    Arms and Interventions

    Arm Intervention/Treatment
    Participants

    Participants with Multiple Sclerosis who meet eligibility criteria.

    Outcome Measures

    Primary Outcome Measures

    1. Change in Cognitive Function - Ambulatory measurement via Dot Memory Test [Baseline up to year 2]

      Reported in terms of Euclidian distance/error Cognition Covariates may include: age, sex, disease duration, Multiple Sclerosis (MS) subtype (relapsing vs. progressive subtypes combined), personality variables, and cognitive reserve (education plus scores on test of vocabulary).

    2. Change in Cognitive Function - Ambulatory measurement via Symbol Search Test [Baseline up to year 2]

      Reported in Reaction Time (milliseconds) Cognition Covariates may include: age, sex, disease duration, Multiple Sclerosis (MS) subtype (relapsing vs. progressive subtypes combined), personality variables, and cognitive reserve (education plus scores on test of vocabulary).

    3. Change in Cognitive Function - clinic-based neurocognitive measurement via NIH Toolbox Cognitive Battery [Baseline up to year 2]

      Test Battery reported in T-scores. Covariates may include: age, sex, disease duration, MS subtype (relapsing vs. progressive subtypes combined), personality variables, and cognitive reserve (education plus scores on test of vocabulary).

    4. Change in Cognitive Function - clinic-based neurocognitive measurement via Symbol Digit Modalities test [Baseline up to year 2]

      Covariates may include: age, sex, disease duration, MS subtype (relapsing vs. progressive subtypes combined), personality variables, and cognitive reserve (education plus scores on test of vocabulary). The score is the number of correct answers in 90 seconds. Higher scores indicates better attention and processing speed.

    5. Change in Cognitive Function - clinic-based neurocognitive measurement via Paced Auditory Serial Addition Test [Baseline up to year 2]

      Covariates may include: age, sex, disease duration, MS subtype (relapsing vs. progressive subtypes combined), personality variables, and cognitive reserve (education plus scores on test of vocabulary). The score range is 0-60 and higher numbers indicate better sustained attention, speed of information processing, and working memory.

    6. Change in Cognitive Function - clinic-based neurocognitive measurement via Rey Auditory Verbal Learning Test [Baseline up to year 2]

      Covariates may include: age, sex, disease duration, MS subtype (relapsing vs. progressive subtypes combined), personality variables, and cognitive reserve (education plus scores on test of vocabulary). The scores from the test represent the total immediate recall (over 5 learning trials), delayed recall, and recognition. Higher scores indicate better verbal learning and memory.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Inclusion Criteria:
    1. Are able to fluently converse and read in English.

    2. Multiple Sclerosis (MS) diagnosis (confirmed from neurologist, all relapsing and progressive subtypes included)

    3. Ambulate either independently or with the use of a cane or walker (or similar device) for at least 50% of the time at baseline

    Exclusion Criteria:
    1. MS relapse within the past 30 days (may become eligible after 30 days; criteria used at T1, T2, and T3).

    2. Inability to use study data collection tools (i.e., ActiGraph wrist-worn activity watch, smart phone app).

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of Michigan Ann Arbor Michigan United States 48109
    2 Wayne State University Detroit Michigan United States 48202
    3 University of Washington Seattle Washington United States 98195

    Sponsors and Collaborators

    • University of Michigan
    • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    • Wayne State University
    • University of Washington

    Investigators

    • Principal Investigator: Anna Kratz, University of Michigan
    • Principal Investigator: Nora Fritz, Wayne State University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Anna Kratz, Associate Professor of Physical Medicine and Rehabilitation, University of Michigan
    ClinicalTrials.gov Identifier:
    NCT05252195
    Other Study ID Numbers:
    • HUM00199732
    • R01HD102337-01
    First Posted:
    Feb 23, 2022
    Last Update Posted:
    Aug 15, 2022
    Last Verified:
    Aug 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Anna Kratz, Associate Professor of Physical Medicine and Rehabilitation, University of Michigan
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 15, 2022